^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anal Carcinoma

    1d
    Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Jiataile (sacituzumab tirumotecan)
    4d
    Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • capecitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    7d
    Painless perianal mucinous adenocarcinoma: A case report and literature review. (PubMed, Oncol Lett)
    The patient underwent radical local wide resection 1 month later, and no recurrence or metastasis was observed during a follow-up period of 12 months. The present case report provides a real-world reference for the clinical diagnosis, selection of treatment plans and evaluation of the prognosis of painless PMA.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CDX2 (Caudal Type Homeobox 2) • MUC2 (Mucin 2)
    |
    KRAS G12D • KRAS G12
    7d
    Clinicopathology of adenocarcinoma originating from the anal gland with immunohistochemical expressions of GATA3 and TTF-1: a case report and literature review. (PubMed, Front Oncol)
    The patient received postoperative radiotherapy. At 6 months of follow-up, metastasis to the right inguinal lymph nodes was identified.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NKX2-1 (NK2 Homeobox 1) • VIM (Vimentin) • CDX2 (Caudal Type Homeobox 2) • GATA3 (GATA binding protein 3)
    |
    KRAS mutation • BRAF mutation • NRAS mutation
    13d
    RC09-FIAS: The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery (clinicaltrials.gov)
    P=N/A, N=520, Recruiting, The First Hospital of Jilin University | Not yet recruiting --> Recruiting
    Enrollment open
    26d
    GI22-588: Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer (clinicaltrials.gov)
    P2, N=23, Recruiting, Dustin Deming | Trial completion date: Apr 2027 --> Apr 2029 | Trial primary completion date: Dec 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel
    27d
    Populational analysis of the mortality-to-incidence ratio across 20 cancer groupings in the Russian Federation. (PubMed, J Glob Health)
    This suggests that population-level differences in MIR and subsequent cancer outcomes are influenced by region, culture, and socioeconomic variations. These findings may inform public health policy on intersectional disparities in MIR across different populations in the Russian Federation, with applicability to other countries.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    27d
    PEACHES 2: Improving Clinic Delivery of HIV-related Anal Health Services (clinicaltrials.gov)
    P=N/A, N=8, Not yet recruiting, Albert Einstein College of Medicine
    New trial
    1m
    FRACAS: Towards an Understanding of Barriers and Delays in the Diagnosis of Anal Cancer (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Centre Hospitalier Intercommunal Creteil
    New trial
    1m
    Detecting HPV DNA in Anal and Cervical Cancers (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, University of Chicago | Suspended --> Recruiting
    Enrollment open
    1m
    Challenges and limitations of anal cancer and precancer screening among people with HIV in a real-world setting. (PubMed, Infection)
    Routine anal-cytology screening in an unsystematically selected cohort of 434 PWH contributing 1,383 person-years of F/U identified 7 cases of high-grade precancerous lesions and 1 asymptomatic AC. Important challenges included low uptake, limited specificity of cytology, inconsistent adherence to F/U recommendations, and insufficient availability of HRA. Improved communication of HIV-care-providers with all involved parties will be a key requirement for improving efficiency and outcomes.
    Journal • Real-world evidence
    |
    CD4 (CD4 Molecule)
    1m
    Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma. (PubMed, Nat Commun)
    During surveillance, ctDNA re-emergence precedes clinical or radiographic relapse in every case. These findings support the consideration of ctDNA as a dynamic, treatment-responsive biomarker warranting prospective validation for risk-adapted surveillance and adjuvant therapy in ASCC.
    Journal • Circulating tumor DNA
    |
    Signatera™